Tag: Redcliffe Labs

  • Redcliffe appoints Ishaan Khanna as new director – reproductive medicine & genetics

    Redcliffe appoints Ishaan Khanna as new director – reproductive medicine & genetics

    New Delhi: Redcliffe Lifetech US and India unit Redcliffe Labs, on 26 May 2022 announced Ishaan Khanna as director – reproductive medicine and genetics.

    Ishaan is a techno-commercial leader with over 19 years of experience in institutional and commercial healthcare businesses. He has effectively built organizations from the ground up and demonstrated success in establishing successful; diagnostic business models in India and abroad.

    He started his career as a scientist with assignments spanning across Australia and the UK. After coming back to India he worked in business development leadership roles in Biotech and pharma companies such as Avesthagen and Krishna Antioxidants.

    His last assignment was at Lifecell where he was the CEO, Biobank and Diagnostics where he spent over a decade.

    He also brought some of the key diagnostic platforms to India for the first time such as QFPCR and rapid genetic testing to support the need of sick infants and pregnant women and building leadership in domains such as newborn screening. In his previous roles, he has built a pan India network of labs and efficient networks, something which he wishes to do at a much larger scale at Redcliffe.

    It is also noteworthy to mention that Ishaan has been facilitated with various awards such as the Best Healthcare CEO, Sustainability leader and Start-up Baron.

    Ishaan is a gold medalist in bachelors biotechnology, Manipal University, Kasturba Medical College/ Manipal Lifescience School India; and holds masters in biotechnology and masters in enterprise, University of Manchester.

    Redcliffe Labs founder Dheeraj Jain said, “Ishaan comes with a rich experience and his work reflects his interest in taking healthcare to the masses, which is exactly in sync with Redcliffe’s philosophy. We are confident that he will perfectly lead this role. This appointment is also important as the Reproductive Medicine and Genetics market continues to grow and evolve, offering great opportunities for players like us in this space. As we continue to experience strong growth momentum, we feel having the right team is key.”

    Newly appointed Redcliffe Labs director – reproductive medicine and genetics Ishaan Khanna said, “I am honoured to be associated with Redcliffe Labs at a time when the healthcare and genetics industry in India is witnessing upward growth. I am looking forward to being a part of the Redcliffe team and its growth story.”

  • Redcliffe Labs onboards Gautam Gambhir as brand ambassador

    Redcliffe Labs onboards Gautam Gambhir as brand ambassador

    Mumbai: Redcliffe Labs, also known as Redcliffe Life Diagnostics has announced Gautam Gambhir as its national brand ambassador to promote the access and right to good health amongst all Indians.

    “Gambhir is among the most-admired Indian cricketers and is an embodiment of good health. Thus, he would be the perfect harbinger to make people aware of the role of regular diagnostics in ensuring good health,” said the brand on Monday.

    Redcliffe Labs founder Dheeraj Jain said the company is delivering on its mission by doing home sample collection from our collection centers, online consultation, building labs across India that are digital-first. “With Gautam as part of the team, we intend to educate people about the benefits of getting regular health checkups and how such check-ups cover almost a hundred tests that can help prevent fatal diseases if diagnosed in time,” he added.

    “The second wave of the pandemic has been an eye-opener and now it is time to change completely towards preventive health,” said Gambhir elaborating on the association. “Redcliffe’s core focus is to build on this and provide routine health test packages to all fellow Indians no matter what. It is set to make real disruption and I am with them to reach every possible pin code of Bharat and give real access to healthcare and diagnostics.”